

Modeling the complex exposure history of smoking in predicting bladder cancer: a pooled analysis of 15 case-control studies.

Frits H.M. van Osch* (1, 2); Jelle Vlaanderen (3); Sylvia H.J. Jochems (1, 2); Cristina Bosetti, (4); Jerry Polesel (5); Stefano Porru (6,7); Angela Carta (7,8); Klaus Golka (9); Xuejuan Jiang (10, 11); Mariana C. Stern (10); Wei-De Zhong (12); Eliane Kellen, (13); Hermann Pohlabein (14); Li Tang (15); James Marshall (15); Gunnar Steineck (16); Margaret R. Karagas (17); Kenneth C. Johnson (18); Zuo-Feng Zhang (19); Jack A. Taylor (20); Carlo La Vecchia (21); Richard T. Bryan MD (2); Frederik J. van Schooten (22); Anke Wesselius (1); Maurice P. Zeegers (1, 2, 23)

1. Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, Maastricht, The Netherlands
2. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
3. Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
4. Unit of Cancer Epidemiology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri Via Giuseppe La Masa 19 - 20156 Milan, Italy
5. Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN), Italy,
6. Department of Diagnostics and Public Health, Section of Occupational Health, University of Verona, Italy
7. University Research Center "Integrated Models for Prevention and Protection in Environmental and Occupational Health" MISTRAL, University of Brescia, Italy

8. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
9. Leibniz Research Centre for Working Environment and Human Factors, Sektion Lebenswissenschaften Dortmund, Germany
10. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
11. Department of Ophthalmology, University of Southern California, Los Angeles, CA, USA
12. Department of Urology, Guangzhou First People's Hospital, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, China
13. Leuven University Centre for Cancer Prevention (LUCC), Leuven, Belgium
14. Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany
15. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
16. Department of Oncology & Pathology, Division of Clinical Cancer Epidemiology, Karolinska Hospital, Stockholm, Sweden
17. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
18. Department of Epidemiology and Community Medicine, University of Ottawa, ON, Canada
19. Departments of Epidemiology, UCLA Center for Environmental Genomics, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA

20. Epidemiology Branch, and Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA
21. Department of Clinical Medicine and Community Health – Università degli Studi di Milano, 20133, Milan, Italy
22. Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
23. Department of Complex Genetics, Public Health and Primary Care (School CAPHRI), Maastricht University, Maastricht, The Netherlands.

*Corresponding author. Frits H.M. van Osch, Department of Complex Genetics, PO Box 616, 6200 MD Maastricht, The Netherlands. Telephone: +31 43 388 1991 E-mail:

f.vanosch@maastrichtuniversity.nl

Keywords: bladder cancer, smoking history, pooled analysis

Acknowledgments: We acknowledge all principal investigators of the studies included in the BLEND consortium for their willingness to participate in this collaborative project. This study was partly funded by the World Cancer Research Fund.

Conflict of interest: None declared

Data availability: Computing code is available by request to the corresponding author. Data from this consortium is not available offsite and cannot be shared online.

Word count (excluding 214 word abstract): 3149

Abstract

Background

Few studies have modeled smoking histories by combining smoking intensity and duration to show what profile of smoking behavior is associated with highest risk of bladder cancer. This study aims to provide insight into the association between smoking exposure history and bladder cancer risk by modeling both smoking intensity and duration in a pooled analysis.

Methods

We used data from 15 case–control studies included in the BLadder cancer Epidemiology and Nutritional Determinants (BLEND) study, including a total of 6,874 cases and 17,727 controls. To jointly interpret the effects of intensity and duration of smoking, we modeled excess odds ratios (EOR) per pack–year by intensity continuously to estimate the risk difference between smokers with long duration/low intensity and short duration/high intensity.

Results

The pattern observed from the pooled EOR model indicated that for a fixed number of pack–years, smoking for a longer duration at lower intensity was more deleterious for bladder cancer risk than smoking more cigarettes/day for a shorter duration. We observed similar patterns within individual study samples.

Conclusions

This pooled analysis shows that long duration/low intensity smoking is associated with a greater increase in bladder cancer risk than short duration/ high intensity smoking within equal pack–year categories, thus confirming studies in other smoking-related cancers and demonstrating that reducing exposure history to a single metric such as pack–years was too restrictive.

Introduction

Smoking is an important modifiable risk factor for urothelial bladder cancer and studies demonstrate a differential dose–response pattern for intensity and duration(1). Many studies have investigated smoking behavior in relation to UBC, showing separate risk estimates for intensity, duration and pack–year, but to our knowledge only a few studies have modeled complex smoking histories including all aspects of exposure such as duration, intensity, and time since smoking cessation(2,3).

Most studies establishing the association between smoking history and various diseases use cumulative exposure (i.e. pack–years) in an attempt to go beyond smoking status only(4). However, more recently, consensus has been reached that modeling pack–years alone is not sufficient to identify possible mechanisms underlying such associations(5). Several researchers have discussed whether pack–years should be used to measure effects of smoking or whether pack–years can be useful in making biologically credible models that provide unbiased information on complex smoking exposure histories(5,6), and circumventing multicollinearity issues(7). Although simultaneous and interpretable modeling of the effects of smoking behavior has been a research topic for several decades for other diseases, this have been infrequently investigated in urothelial bladder cancer research(8,9).

Two case–control studies in urothelial bladder cancer both suggested that among equal pack–year categories, individuals who had smoked relatively fewer cigarettes per day for longer duration were at a higher risk of bladder cancer compared to those who smoked more cigarettes per day over a shorter duration(2,3). In these studies, estimates of the excess odds ratio (EOR) per pack–year were compared across categories of smoking intensity. Recently, similar models have been further developed and tested to also include time since smoking cessation(10) or stratification by age category to consider timing of exposure (11).

Using an alternative approach, two other case–control studies data also showed that duration is the over-riding factor in determining the risk of bladder cancer(12,13).

The aim of this study was to investigate the association between cumulative smoking exposure and urothelial bladder cancer risk, and to model and interpret the various smoking effects, in a uniquely large pooled sample of case–control studies.

Methods

Study data

The BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium currently consists of 19 case–control studies and 14 cohort studies investigating the association between lifestyle behaviors and urothelial bladder cancer risk. For this analysis, we included 15 case–control studies providing complete data on smoking behavior, including; smoking status, intensity and duration. These included 6,824 cases and 17,727 controls originating from Italy(13–15), Germany(16,17), Belgium(18), Sweden(19), Canada(20), the USA(21–26) and China(27). All smoking data were either collected through interview-administered questionnaires (n=6) or self-administered questionnaires (n=9). Further details on the methodology of this consortium have been described(28).

Statistical analysis and delivery rate of exposure

We used a statistical approach described by Vlaanderen et al. (10). The pooled smoking data were divided into quintile categories of pack–years, years of smoking, cigarettes per day and time since smoking cessation. We obtained odds ratios (ORs) for these categories using a multilevel random effect logistic regression model adjusting for study, age, and sex as covariates. Subsequently, total pack–years were cross-classified by cigarettes smoked per day and years of smoking to estimate the ORs in combined exposure categories with never smokers as the reference group. Finally, we fitted an exponential model to estimate the EOR per pack–year by smoking intensity to investigate the independent effect of

cigarette smoking duration and intensity of cigarette smoking on bladder cancer risk. In other words, with these models, long duration/low intensity smokers are compared to short duration/high intensity smokers with equal pack-years.

We used the model:

$$OR(d) = 1 + \beta d \times \exp(g1(n))$$

where the model was fitted using continuous pack-years (d), continuous intensity (n) and $g1$ as a three-knot restricted cubic spline function of continuous smoking intensity (knots located at 20th, 50th, and 80th percentile of the distribution of intensity of all smokers). This model was applied to each of the 15 studies.

The results from such models describe delivery rate patterns of exposure to tobacco smoking in relation to urothelial bladder cancer risk. The delivery rate is described through estimating how increasing intensity or duration within a fixed number of pack-years influences bladder cancer risk. For example, an inverse exposure rate effect for intensity would mean that the EOR/pack-year (the strength of association) decreases with more cigarettes smoked per day (and thus decrease duration) or alternatively the OER/pack-year increases with fewer cigarettes per day (and increased duration). Consequently, for two individuals with equal total pack-years, greater risk accrues to the individual smoking for longer duration at lower intensity.

A sensitivity analysis was performed with data from 5 studies that provided detailed data on time since smoking cessation by adding an extra 3-knot restricted cubic spline (knots at the 20th, 50th and 80th percentiles of the distribution of time since cessation of all former smokers) to the model, since incorporating time since cessation into these models might provide a better fit with the data(10). Additionally, different knot locations (at the 10th, 50th, and 90th and 5th, 50th, and 95th percentiles) were applied to assess the robustness of the associations. The fit of the models with different knot locations were tested using the Akaike

information criterion (AIC). 95% confidence intervals (CIs) for the EOR models were estimated through bootstrapping via 1,000 replications of the original data. The 2.5th and the 97.5th percentile of the subsequent distribution are shown in the fitted model. To assess the level of heterogeneity underlying this EOR model, we also repeated it in individual BLEND study populations.

Results

Smoking characteristics in included studies

Table 1 shows baseline characteristics for all included case-control studies. In most studies, at least 80% of current smokers at baseline smoked more than 10 cigarettes a day. The only study in which this proportion was much lower than the mean proportion for both current smokers (14%) and former smokers (4%) was the Swedish study (19) (Table 1). Nine of the 15 studies demonstrated that 90% of current smokers had smoked for at least 20 years. This percentage was lower among former smokers (between 70% and 80%) (Table 1). One study from the USA(22) provided details on smoking behavior among current smokers only.

Risk estimates for smoking behavior

Based on the pooled results, current smokers had a higher urothelial bladder cancer risk than never smokers (OR=2.23, 95% CI=2.05-2.42) (Table 2). Tests for linear trend showed increasing risks across quintile categories of intensity, duration and pack-years (p -values<0.001). Furthermore, smoking cessation was related to a lower bladder cancer risk compared to current smokers (Table 2), with an OR of 0.40 (95% CI=0.32-0.51) for those who had quit smoking more than 30 years before diagnosis. Bladder cancer risk for those who had quit smoking 30 years prior to diagnosis was very similar to those who had never smoked (OR=1.04, 95% CI=0.81-1.32).

Delivery rate patterns of exposure to smoking in relation to UBC risk

We calculated fifteen ORs, with never smokers as reference category, in the analysis stratified by intensity quintile (Figure 1), while 20 ORs were estimated in the analysis stratified by duration quintile (eFigure 1; <http://links.lww.com/EDE/B457>) because data were sparse in the intensity categories. None of the associations showed any departures from linearity ($p > 0.05$ for all categories), which means that the EOR model as it is presented is valid in meeting the assumption about linearity of association between exposure and disease.

The EOR per pack–year and 95% CI by continuous smoking intensity (cigarettes/day) resulting from the cubic spline model are plotted in Figure 2. Additionally, the slope resulting from the model including splines for TSC is also shown. The model excluding TSC had a slightly better fit to the data (AIC=23,14) compared to the model including TSC (AIC=24,22), probably because the effect of TSC was heterogeneous between the few included studies. Both curves show an inverse delivery rate pattern, whereby with increasing cigarettes smoked per day (and decreasing duration) the EOR per pack–year decreases. This indicates that for equal pack–years, smoking for a longer duration (at few cigarettes/day) is more strongly associated with UBC risk than smoking more cigarettes per day (for a shorter duration). As can be observed from the bootstrapped 95% CI, the plotted curve had the highest number of participants for individuals smoking between 10 and 40 cigarettes per day, which included 79% of all smokers in this consortium, and therefore the shape of the curve is most reliable on this interval.

Heterogeneity was small among the 10 individual studies in which EOR models could be fit with the original spline settings (eFigure 2A; <http://links.lww.com/EDE/B457>). For three studies(14,23,25) the model did not fit because of their data distribution (e.g. 19 cigarettes per day represented the 44th percentile and 20 cigarettes per day represented the 82th percentile of the data), and there was limited power within 2 studies(16,27) (too many

levels of intensity with no cases). When moving the splines to positions fitting the data distribution in the three studies with a different data distribution, the three added curves show a similar shape to the EOR curves from the 10 studies that were estimated with the original spline settings (eFigure 3; <http://links.lww.com/EDE/B457>). Additionally, the EOR models within the 3 studies that included sufficient data on TSC(15,18,20) were also similar (eFigure 2B; <http://links.lww.com/EDE/B457>).

Discussion

We have provided insight into the complex exposure patterns of lifetime smoking behavior and the impact on UBC risk. We have shown an inverse delivery rate pattern indicating that, for equal pack-years of smoking, fewer cigarettes per day over a longer duration is more deleterious for urothelial bladder cancer risk than smoking more cigarettes per day over a shorter duration. The results of this pooled analysis of 15 case-control studies are in line with data from two other previous case-control studies on bladder cancer applying a similar approach (2,3).

Robustness of results

We applied the model as described by Vlaanderen et al, but a similar approach was first described in a lung cancer study(29), known as the L-C (Lubin-Caparaso) model, which has also been applied in a pooled analysis of case-control studies on head and neck cancer(30) and in two individual urothelial bladder cancer case-control studies(2,3).

Alongside these models, Brennan et al described a different approach in 2000 that was based on stratification of both duration and intensity and estimating ORs in all strata. They also observed that duration was more important in predicting bladder cancer risk than intensity(12). Nevertheless, the approach Brennan et al. took does not allow for an unambiguous interpretation of the separate RRs; the question remains whether the increase in risk derives from duration or from pack-years, which increases concurrently. The modeling

approach applied in our study does answer this question since the results show the risk difference between long duration/low intensity and short duration/high intensity smokers with equal pack–years.

Similar ORs were observed for both women and men, although more men smoked at least 10 cigarettes per day (86%) compared to women (73%), possibly explaining differences in precision of risk estimates, in addition to the smaller sample of women in the included studies. Furthermore, observed ORs for smokers might be underestimated since the pooled OR for current smokers was markedly lower than observed in a large meta-analysis⁽¹⁾ (OR=2.23 in the current sample vs OR=3.14 in the meta-analysis). This might be explained by some misclassification of smoking information collected through self-administered questionnaires in the 15 included studies or differences in data collection in the meta-analysis.

Notwithstanding, the selection of 15 studies that agreed to participate in this consortium might also not be representative of all bladder cancer case–control studies present, since most participating studies are from either Europe and the USA.

Little heterogeneity in the range of predicted EORs per pack–year by cigarettes per day between the included studies was observed (eFigure 2; <http://links.lww.com/EDE/B457>). However, some heterogeneity in magnitude of estimated EORs per pack–year remains between the studies, which may be explained by several factors such as geographic location⁽¹⁾ and calendar year in which cases and controls were recruited⁽³¹⁾. Since only five studies provided sufficient data on TSC, this pooled analysis might not have had sufficient power to include TSC as an extra spline.

Strengths and limitations of the EOR model and interpretation of results

Although the EOR model can provide a more detailed insight into the association between smoking behavior and disease risk, there are some other factors not in this model

that also need to be considered. Since a more vigorous inhalation pattern has been shown to be associated with a higher UBC risk(32,33), the observed inverse delivery rate pattern might reflect differences in inhalation patterns among cigarette smokers. It is generally believed that light smokers inhale more vigorously compared to heavier smokers to achieve the same amount of nicotine consumption(34,35), therefore possibly confounding the risk estimates comparing heavy to light smokers. However, inhalation was not found to be a confounder of pack-years-adjusted cigarettes per day patterns in a lung cancer study(29). Data on inhalation patterns was not available for the study participants within BLEND.

Moreover, since no data were available on time periods during which study participants might have smoked less (or more) than their average estimated intensity we could not account for this.

Due to the retrospective nature of data collection in case-control studies including such detailed data on smoking behavior would not have been possible in this pooled analysis; however, in prospective studies such periodical changes in smoking intensity could be accounted for when applying the EOR models by adding TSC or time since moderation splines if data is gathered. Nevertheless, the 5 case-control studies that did gather data on TSC showed a similar shape of the EOR curve (Figure 2). This EOR model provides one of the most detailed UBC risk predictions following different durations and intensities of smoking. Nevertheless, there have been other methods to model smoking history in relation to cancer such as the comprehensive smoking index which also incorporates intensity, duration and time since cessation(36).

Smoking behavior and molecular pathways to bladder carcinogenesis

Tobacco smoke contains many carcinogens that can contribute to carcinogenesis in the bladder. These carcinogens can form DNA adducts and, when multiple types of DNA adducts are combined, they contribute greatly to human cancer risk(37). Several studies have

shown that nicotine-derived nitrosamine ketones (NNK), methyl and other DNA adducts are more frequently present in UBC patients who have smoked compared to those who have never smoked(38,39). Nevertheless, it is not clear how NT2 status is involved in an inverse smoking intensity effect in at population level. It has not been measured whether rapid acetylators are more likely to be high intensity/short duration smokers. Moreover, there is heterogeneity in the efficiency of DNA repair pathways between individuals; for example, those who have a slow N-acetyltransferase phenotype have a higher risk of UBC when they smoke(40), and DNA repair processes can also be negatively influenced by longer smoking duration or higher cumulative exposure (in pack–years) (41). This indicates that the DNA adduct pathway of UBC pathogenesis is important in smoking-related UBC. Although not directly implied from our data as we did not measure DNA adducts, the risk difference between long duration/low intensity smokers and short duration/high intensity smokers could be explained by the longer exposure period for accumulation of smoking-related DNA adducts in long duration/low intensity smokers. The results from our study, as well as of other studies in UBC(2,3), lung cancer(10,29), and head and neck cancer(30), are consistent in showing that smoking fewer cigarettes over a longer duration increases disease risk more than smoking at a higher intensity for a shorter duration when pack–years are equal. Therefore, future studies should investigate differences in DNA repair pathways between long duration/low intensity versus short duration/high intensity smokers as the studies discussed in this paragraph focus only on intensity or duration separately in relation to DNA adducts. Nevertheless, these results have major implications for prevention at public health level and can impact the public’s perception on smoking and health risks.

Conclusion

We have demonstrated that long duration/low intensity smoking behavior is most strongly associated with UBC risk within equal pack–year categories in this pooled analysis, thereby confirming studies in two case–control studies on UBC as well as other smoking-related cancers. Furthermore, with this model we found that reducing complex exposure history to a single metric such as pack–years was too restrictive, and future research should focus on interpretable ways to model complex cumulative exposures such as lifetime smoking behavior.

ACCEPTED

References

1. van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. *Int J Epidemiol*. 2016;45(3):857–70.
2. Lubin JH, Kogevinas M, Silverman D, Malats N, Garcia-Closas M, Tardón A, et al. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. *Int J Epidemiol*. 2007 Feb 1;36(1):236–41.
3. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case–control study of smoking and bladder cancer risk: emergent patterns over time. *J Natl Cancer Inst*. 2009 Nov 18;101(22):1553–61.
4. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, et al. Risk of bladder cancer by source and type of tobacco exposure: a case–control study. *Int J cancer*. 1989 Oct 15;44(4):622–8.
5. de Vocht F, Burstyn I, Sanguanchaiyakrit N. Rethinking cumulative exposure in epidemiology, again. *J Expo Sci Environ Epidemiol*. 2015 Sep 20;25(5):467–73.
6. Thomas DC. Invited Commentary: Is It Time to Retire the ‘Pack–years’ Variable? Maybe Not! *Am J Epidemiol*. 2014 Feb 1;179(3):299–302.
7. Leffondre K, Abrahamowicz M, Siemiatycki J, Rachet B. Modeling Smoking History: A Comparison of Different Approaches. *Am J Epidemiol*. 2002 Nov 1;156(9):813–23.
8. Moolgavkar SH, Dewanji A, Luebeck G. Cigarette smoking and lung cancer: reanalysis of the British doctors’ data. *J Natl Cancer Inst*. 1989;81(6):415–20.
9. Thomas D. *Statistical methods in environmental epidemiology*. 2009;
10. Vlaanderen J, Portengen L, Schüz J, Olsson A, Pesch B, Kendzia B, et al. Effect Modification of the Association of Cumulative Exposure and Cancer Risk by Intensity

- of Exposure and Time Since Exposure Cessation: A Flexible Method Applied to Cigarette Smoking and Lung Cancer in the SYNERGY Study. *Am J Epidemiol.* 2014 Feb 1;179(3):290–8.
11. Flanders WD, Lally CA, Zhu B-P, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. *Cancer Res.* 2003 Oct 1;63(19):6556–62.
 12. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case–control studies. *Int J Cancer.* 2000 Apr 15;86(2):289–94.
 13. Polesel J, Bosetti C, di Maso M, Montella M, Libra M, Garbeglio A, et al. Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. *Cancer Causes Control.* 2014 Sep 26;25(9):1151–8.
 14. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. *Int J Cancer.* 2004 Jul 1;110(4):598–604.
 15. Randi G, Pelucchi C, Negri E, Talamini R, Galeone C, Franceschi S, et al. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. *Int J Cancer.* 2007 Dec 15;121(12):2748–52.
 16. Pohlabein H, Jöckel K-H, Bolm-Audorff U. Non-occupational risk factors for cancer of the lower urinary tract in Germany. *Eur J Epidemiol.* 1999;15(5):411–9.

17. Golka K, Heitmann P, Gieseler F, Hodzic J, Masche N, Bolt HM, et al. Elevated Bladder Cancer Risk Due to Colorants—A Statewide Case-control Study in North Rhine-Westphalia, Germany. *J Toxicol Environ Heal Part A*. 2008 Jun 3;71(13-14):851-5.
18. Kellen E, Zeegers M, Paulussen A, Van Dongen M, Buntinx F. Fruit consumption reduces the effect of smoking on bladder cancer risk. The Belgian case control study on bladder cancer. *Int J Cancer*. 2006 May 15;118(10):2572-8.
19. Augustsson K, Skog K, Jägerstad M, Dickman PW, Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. *Lancet*. 1999 Feb 27;353(9154):703-7.
20. Gaertner RRW, Trpeski L, Johnson KC. A case-control study of occupational risk factors for bladder cancer in Canada. *Cancer Causes Control*. 2004 Dec;15(10):1007-19.
21. Jiang X, Castela JE, Yuan JJ-M, Stern MC, Conti D V., Cortessis VK, et al. Cigarette smoking and subtypes of bladder cancer. *Int J Cancer*. 2012 Feb 15;130(4):896-901.
22. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Consumption of Raw Cruciferous Vegetables is Inversely Associated with Bladder Cancer Risk. *Cancer Epidemiol Biomarkers Prev*. 2008 Apr 1;17(4):938-44.
23. Quirk JT, Li Q, Natarajan N, Mettlin CJ, Cummings KM. Cigarette Smoking and the Risk of Bladder Cancer in Men and Women. *Tob Induc Dis*. 2004 Sep 15;2(3):141.
24. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. *Environ Health Perspect*. 1998 Aug;106 Suppl 4(Suppl 4):1047-50.

25. Cao W, Cai L, Rao JJ-YJ, Pantuck A, Lu MM-LM, Dalbagni G, et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. *Cancer*. 2005 Dec 1;104(11):2400–8.
26. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. *Cancer Res*. 1998 Aug 15;58(16):3603–10.
27. Hemelt M, Hu Z, Zhong Z, Xie L-P, Wong YC, Tam P-C, et al. Fluid intake and the risk of bladder cancer: Results from the South and East China case-control study on bladder cancer. *Int J Cancer*. 2010 Feb 1;127(3):638–45.
28. Goossens ME, Isa F, Brinkman M, Mak D, Reulen R, Wesselius A, et al. International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. *Arch Public Heal*. 2016 Dec 6;74(1):30.
29. Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. *Cancer Epidemiol Biomarkers Prev*. 2006 Mar 1;15(3):517–23.
30. Lubin JH, Purdue M, Kelsey K, Zhang Z-F, Winn D, Wei Q, et al. Total Exposure and Exposure Rate Effects for Alcohol and Smoking and Risk of Head and Neck Cancer: A Pooled Analysis of Case-control Studies. *Am J Epidemiol*. 2009 Oct 15;170(8):937–47.
31. Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. *BJU Int*. 2013 Jul;112(2):169–75.

32. Zeegers MPA, Goldbohm RA, van den Brandt PA. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). *Cancer Causes Control*. 2002;13(1):83–90.
33. López-Abente G, González CA, Errezola M, Escolar A, Izarzugaza I, Nebot M, et al. Tobacco Smoke Inhalation Pattern, Tobacco Type, and Bladder Cancer in Spain. *Am J Epidemiol*. 1991 Oct 15;134(8):830–9.
34. Fidler JA, Stapleton JA, West R. Variation in saliva cotinine as a function of self-reported attempts to reduce cigarette consumption. *Psychopharmacology (Berl)*. 2011 Oct 10;217(4):587–93.
35. Patterson F, Benowitz N, Shields P, Kaufmann V, Jepsen C, Wileyto P, et al. Individual differences in nicotine intake per cigarette. *Cancer Epidemiol Biomarkers Prev*. 2003;12(5):468–71.
36. Leffondré K, Abrahamowicz M, Xiao Y, Siemiatycki J. Modeling smoking history using a comprehensive smoking index: application to lung cancer. *Stat Med*. 2006 Dec 30;25(24):4132–46.
37. Poirier MC. Chemical-induced DNA damage and human cancer risk. *Discov Med*. 2012 Oct;14(77):283–8.
38. Jin F, Thaiparambil J, Ramya Donepudi S, Vantaku V, Waduge D, Piyarathna B, et al. Tobacco-specific carcinogens induce hypermethylation, DNA adducts and DNA damage in Bladder Cancer. 2017;
39. Talaska G, al-Juburi AZ, Kadlubar FF. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. *Proc Natl Acad Sci U S A*. 1991 Jun 15;88(12):5350–4.

40. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. *Cancer Epidemiol Biomarkers Prev.* 2001;10(12):1249–52.
41. Corral R, Lewinger JP, Van Den Berg D, Joshi AD, Yuan J-M, Gago-Dominguez M, et al. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. *Int J Cancer.* 2014 Jul 15;135(2):335–47.

ACCEPTED

Legends Tables & Figures

Table 1. Number of bladder cases and controls by smoking status included in the BLEND consortium study.

Table 2. Odds ratios (OR) and 95% confidence intervals (95% CI) for bladder cancer according to smoking status, quintile categories for pack–years, duration and intensity, and time since smoking cessation overall and by sex.

Figure 1. Odds ratios (OR) for bladder cancer by cross-classified categories of pack–years and quintile categories of number of cigarettes smoked per day (CPD). Lines indicate fitted linear odds ratio models in pack–years, bars indicate 95% confidence intervals. Pooled data was limited to never and current smokers.

Figure 2. Estimated excess odds ratio (EOR) per pack–year for bladder cancer by cigarettes per day with bootstrapped 95% confidence intervals. The dotted line indicates a model including an extra spline for time since smoking cessation. Triangles depict locations of the knots of the restricted cubic splines (20th, 50th and 80th percentile).

eFigure 1. Odds ratios (OR) for bladder cancer by cross-classified categories of pack–years and quintile categories of years of smoking. Lines indicate fitted linear odds ratio models in pack–years, bars indicate 95% confidence intervals. Pooled data was limited to never and current smokers.

eFigure 2. Excess odds ratio (EOR) per pack–year by smoking intensity (cigarettes/day) stratified by study. Model without time since smoking cessation spline (panel A) and model with time since smoking cessation spline (panel B). Study numbers refer to reference number within this paper (see Table 1).

eFigure 3. Excess odds ratio (EOR) per pack–year by smoking intensity stratified by study, including curves for three studies (116, 125, 132) that had to be fit with alternative spline locations. Study numbers refer to reference number within this paper (see Table 1).

Table 1. Smoking behavior and number of cases and controls in all included BLEND studies

Study location	All cases & controls (n=24551)				Current smokers (n=9147)		Former smokers (n=6928)	
	Total (cases/controls)	Current	Former	Never	>10 cigarettes/day	>20 years of cigarette smoking	>10 cigarettes/day	>20 years of cigarette smoking
Total	24551 (6824 / 17727)	9147	6928	8476	4523	6179	4751	5044
Europe								
Belgium ¹³	582 (200 / 382)	105	286	191	88 (84%)	103 (98%)	237 (83%)	204 (71%)
Germany (1) ¹⁴	561 (278 / 283)	143	264	154	111 (78%)	136 (95%)	168 (64%)	181 (69%)
Germany (2) ¹⁵	421 (191 / 230)	89	198	135	79 (90%)	84 (95%)	164 (83%)	138 (70%)
Italy (1) ¹⁶	1734 (702 / 1032)	691	529	514	578 (84%)	637 (92%)	437 (83%)	433 (82%)
Italy (2) ¹⁷	413 (200 / 213)	162	181	70	130 (80%)	117 (72%)	147 (81%)	116 (64%)
Italy (3) ¹⁸	1324 (669 / 655)	418	573	333	377 (90%)	404 (97%)	494 (86%)	455 (79%)
Sweden ¹⁹	748 (240 / 508)	241	242	265	31 (14%)	225 (93%)	8 (4%)	196 (81%)
North America								
Canada ²⁰	5689 (898 / 4800)	1205	2390	2103	1078 (89%)	1023 (85%)	1872 (78%)	1462 (61%)
USA (1) ²¹	3179 (1641 / 1538)	1240	1133	806	1085 (88%)	698 (56%)	1068 (94%)	1065 (94%)
^a USA (2) ²²	533 (122 / 411)	163	-	370	157 (96%)	155 (95%)	-	-
USA (3) ²³	6834 (399 / 6435)	3363	125	3346	2585 (82%)	2203 (66%)	97 (82%)	91 (73%)
USA (4) ²⁴	664 (374 / 290)	175	301	188	164 (95%)	160 (91%)	262 (87%)	200 (66%)
USA (5) ²⁵	451 (184 / 267)	63	229	159	55 (87%)	47 (75%)	213 (93%)	162 (71%)
USA (6) ²⁶	457 (243 / 214)	89	249	119	86 (97%)	84 (94%)	231 (93%)	175 (70%)
Asia								
China ²⁷	952 (483 / 469)	330	228	394	277 (84%)	313 (95%)	184 (81%)	187 (82%)

^aThis study provided duration and intensity data for current smokers only

Table 2. Odds ratios (OR) and 95% confidence intervals (95% CI) for bladder cancer according to smoking status, quintile categories for pack-years, duration and intensity, and time since smoking cessation overall and by sex.

	All subjects				Men				Women			
	Cases (n=6824)	Controls (n=17727)	OR ^a	95% CI	Cases (n=5305)	Controls (n=9320)	OR ^a	95% CI	Cases (n=1519)	Controls (n=8407)	OR ^a	95% CI
Smoking status												
Never smoker	1493	7654	1,00	ref	834	2662	1,00	ref	659	4992	1,00	ref
Former smoker	2765	4163	1,94	1.78-2.11	2337	3092	2,05	1.85-2.27	428	1071	1,85	1.57-2.19
Current smoker	2566	5910	2,23	2.05-2.42	2134	3566	2,29	2.06-2.53	432	2344	2,24	1.91-2.62
Pack-years												
Quintile 1 (<9)	642	2794	1,18	1.05-1.33	473	1289	1,21	1.05-1.40	169	1505	1,18	0.97-1.45
Quintile 2 (9-17)	684	2191	1,60	1.43-1.80	525	1315	1,50	1.31-1.72	159	876	1,91	1.54-2.38
Quintile 3 (18-30)	1221	2107	2,31	2.09-2.56	1020	1617	2,19	1.94-2.46	201	490	2,72	2.19-3.37
Quintile 4 (31-46)	1248	1446	2,76	2.48-3.06	1054	1099	2,70	2.39-3.05	194	347	3,13	2.49-3.94
Quintile 5 (≥47)	1536	11535	2,96	2.67-3.28	1399	1338	3,01	2.68-3.38	137	197	2,77	2.11-3.65
P for linear trend				<0.001				<0.001				<0.001
Duration (in years)												
Quintile 1 (<16)	603	2492	1,14	1.01-1.28	475	1262	1,20	1.04-1.38	128	1230	1,12	0.89-1.41
Quintile 2 (16-25)	827	2297	1,59	1.43-1.78	686	1344	1,68	1.48-1.92	141	953	1,48	1.18-1.85
Quintile 3 (26-35)	1277	2191	2,24	2.03-2.47	1071	1484	2,31	2.05-2.60	206	707	2,14	1.74-2.62
Quintile 4 (36-43)	1193	1476	2,64	2.38-2.94	968	1165	2,55	2.26-2.89	225	311	3,32	2.67-4.14
Quintile 5 (≥44)	1431	1617	3,10	2.79-3.44	1271	1403	3,18	2.81-3.59	160	214	3,27	2.54-4.21
P for linear trend				<0.001				<0.001				<0.001
Intensity (in cigarettes/day)												
Quintile 1 (<7)	551	1901	1,39	1.22-1.57	394	933	1,37	1.17-1.60	157	968	1,44	1.16-1.79
Quintile 2 (7-10)	775	2932	1,80	1.62-2.01	597	1649	1,74	1.52-1.99	178	1283	1,82	1.48-2.24

Quintile 3 (11-19)	777	1082	2,19	1.95-2.47	648	805	2,15	1.87-2.47	129	277	2,66	2.05-3.44
Quintile 4 (20-29)	1862	2362	2,37	2.16-2.60	1590	1865	2,34	2.09-2.61	272	497	2,85	2.33-3.49
Quintile 5 (≥ 30)	1366	1794	2,62	2.36-2.91	1242	1404	2,70	2.40-3.04	124	390	2,09	1.58-2.74
P for linear trend				<0.001				<0.001				<0.001
Time since smoking cessation^b												
Current smoker	907	1566	1,00	ref	748	1057	1,00	ref	159	509	1,00	ref
1-5 years	220	372	0,93	0.76-1.13	194	275	0,96	0.77-1.19	26	97	0,88	0.54-1.44
6-10 years	193	428	0,76	0.62-0.93	164	294	0,80	0.64-1.00	29	134	0,66	0.41-1.04
11-15 years	171	400	0,72	0.58-0.89	153	272	0,83	0.66-1.05	18	128	0,38	0.22-0.66
16-20 years	138	401	0,59	0.47-0.74	115	279	0,60	0.47-0.77	23	122	0,61	0.37-1.01
21-30 years	198	600	0,58	0.48-0.71	180	410	0,70	0.56-0.87	18	190	0,27	0.16-0.46
>30 years	123	445	0,40	0.32-0.51	113	327	0,48	0.37-0.62	10	118	0,17	0.08-0.33
P for linear trend				<0.001				<0.001				<0.001

^aAdjusted for age. Overall estimates also adjusted for sex.

^bData only present in 5/15 studies.

Figure 1




Figure 2

